AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04145440
Drug: MOR202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received 9 doses of MOR202 as an intravenous infusion over 6 treatment cycles of 28-days each. Dosing occured weekly in Cycle 1 and every 4 weeks in Cycles 2 to 6.
Trial: NCT00398827
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02188225
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/ daily
Trial: NCT01400815
Drug: X-22 Smoking Cessation Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period.
Trial: NCT03404206
Drug: Naproxen Sodium (Aleve, BAY117031)
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 220 mg x 2 tablets, oral, single dose
Trial: NCT03404206
Drug: Ibuprofen (Advil)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg x 2 tablets, oral, single dose
Trial: NCT03499171
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is taken once a day as an add-on to PPI treatment (2x/d)
Trial: NCT03436654
Drug: GnRH agonist/antagonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice, for a total duration not to extend beyond the treatment phase of the protocol or 10 months from the start of investigational agent(s)
Trial: NCT04118933
Drug: JS001
RxNorm normalized name: Janus Kinase Inhibitor JS001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JS001 240mg, Q3W
Trial: NCT00006324
Drug: Ethinyl estradiol/levonorgestrel
RxNorm normalized name: ETHINYL ESTRADIOL/LEVONORGESTREL
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00638859
Drug: Telithromycin (HMR3647)
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00857415
Drug: florbetapir F 18
RxNorm normalized name: Florbetapir F 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
Trial: NCT06185127
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bolus doses of fentanyl (100 μg / 10 ml; 5 ml of the solution or 50 μg fentanyl per bolus, induction dose of 50μg) were administered at 20-minute intervals in between and titrated as needed to obtain the desired sedation depth. No more than 150 μg of fentanyl were administered.
Trial: NCT01199731
Drug: GSK2248761 100 mg once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 100mg capsule OAD plus matching placebo
Trial: NCT00756847
Drug: XL147 (SAR245408),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsules supplied in 25- and 100-mg strengths; daily dosing
Trial: NCT02789111
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily up to 15 doses
Trial: NCT01336296
Drug: mycophenolic acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comparing mycophenolic acid 720mg orally twice daily starting 2 weeks prior to transplant to mycophenolic acid 720mg orally twice daily starting day of transplant.
Trial: NCT02071927
Drug: CB-839
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent CB-839
Trial: NCT02071927
Drug: CB-Aza
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB-839 in combination with standard dose azacitidine
Trial: NCT01701778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal: Levobupivacaine 0.25% 1ml/kg~Intravenous: 10 ml normal saline
Trial: NCT00931853
Drug: SENNA+CASSIA(Naturetti)
RxNorm normalized name: Padang cassia oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
Trial: NCT03635684
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous infusion of Acetaminophen over 20 to 30 minutes, with evaluation of:~* local side effects;~* pain and/or fever;~at time of infusion, after 30 minutes, 60 minutes and 180 minutes.
Trial: NCT00125567
Drug: Levodopa/carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules, 50-150 mg levodopa four times daily, for up to 2 years
Trial: NCT00698425
Drug: Citrate buffer
RxNorm normalized name: Citrate Buffer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
Trial: NCT00557401
Drug: XP19986 SR3, 20 mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP19986 Sustained Release (SR) 20 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
Trial: NCT00557401
Drug: XP19986 SR3, 40 mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP19986 Sustained Release (SR) 40 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
Trial: NCT00557401
Drug: XP19986 SR3, 60 mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP19986 Sustained Release (SR) 60 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
Trial: NCT00557401
Drug: XP19986 SR3, 30 mg BID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XP19986 Sustained Release (SR) 30 mg tablet taken orally, twice daily (BID) for approximately 32 days with titration and taper periods.
Trial: NCT00557401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken orally for approximately 32 days with titration and taper periods.
Trial: NCT04133480
Drug: GWP42003-P
RxNorm normalized name: P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution of 100 milligrams per milliliter (mg/mL) cannabidiol (CBD)
Trial: NCT00319449
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day matching placebo to ezetimibe, orally, daily for 6 weeks, added to ongoing 10 mg atorvastatin
Trial: NCT00455533
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Solution, IV, 600mg/m², Day 1 every 21 days, 12 Weeks
Trial: NCT00455533
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Solution, IV, 60mg/m², Day 1 every 21 days, 12 Weeks
Trial: NCT01437878
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT01715714
Drug: Statin Recapture Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given 12h and 2h before CABG
Trial: NCT01715714
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given 12h and 2h before CABG.
Trial: NCT06304038
Drug: Flu Vaccine
RxNorm normalized name: flu vaccine 2012 (18-64yrs)/PF 27 mcg/0.1 mL INTRADERM SYRINGE (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of quadrivalent split inactivated non-adjuvanted flu vaccine Fluarix Tetra
Trial: NCT03539354
Drug: B-blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standart b-blocker therapy will be administered in each group for AF prophylactics
Trial: NCT00681408
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil placebo pills
Trial: NCT00923936
Drug: Liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m\^2 and bevacizumab every 3 weeks for six cycles.
Trial: NCT02066220
Drug: Reduced-intensity maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starts 6 weeks after radiotherapy. 6 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15, Regimen B: (cycles 2, 4, 6): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks, for a total duration of 27 weeks.~Cumulative doses of chemotherapy drugs: cisplatin 210 mg/m2, lomustine (CCNU) 225 mg/m2, vincristine 18 mg/m2, cyclophosphamide 6 g/m2.
Trial: NCT00077428
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02330679
Drug: Desvenlafaxine
RxNorm normalized name: Desvenlafaxine
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention will consist of a 2-week single-blind placebo run-in phase followed by a 12-week open-label trial with desvenlafaxine (a SNRI medication)
Trial: NCT02066220
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Starts 6 weeks after radiotherapy. 8 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5, 7): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15 Regimen B: (cycles 2, 4, 6, 8): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.~Interval after cycle A: 6 weeks, after cycle B: 3 weeks. Duration 36 weeks. Cumulative doses of chemotherapy drugs: cisplatin 280 mg/m2, lomustine (CCNU) 300 mg/m2, vincristine 24 mg/m2, cyclophosphamide 8 g/m2, carboplatin 1050 mg/m2 (in randomized patients).
Trial: NCT02066220
Drug: Induction Chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 37,5mg/m² in 24h-infusion, days 1 and 2 (If administration of doxorubicin is not deemed appropriate, doxorubicin can be substituted by carboplatin 200mg/m²) VCR 1,5mg/m² (max. dose 2mg) in short infusion, days 1, 15, 29, 43 HD-MTX 5g/m²in two doses (0.5g/m² in 0.5h and 4.5g/m² in 23.5h), days 15 and 29 (+ Leucovorin) Carboplatin 200mg/m² in 1h-infusion, days 43, 44, and 45 MTX 2mg intraventricularly, days 1-4, 15, 16, 29, 30, 43-46
Trial: NCT04689958
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin, pregabalin, or amitriptyline
Trial: NCT01422733
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 10mg/m2/per day PO at bedtime (X12 weeks)
Trial: NCT01422733
Drug: rhCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mcg IV twice
Trial: NCT02066220
Drug: Vinblastin Maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly VBL (5mg/m², max. 10mg/dose) for 24 weeks
Trial: NCT00969813
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 10 mg dose of CP-690,550
Trial: NCT04075110
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet once daily
Trial: NCT02265952
Drug: REGN1500 250 mg SC/15 mg/kg IV/450 mg SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received single dose of REGN1500 subcutaneous (SC) injection of 250 milligrams (mg) at Week 0 (Day 1), followed by single dose of REGN1500 intravenous (IV) injection of 15 milligrams per kilogram (mg/kg) at Week 2 (Day 15) and then followed by 4 doses of REGN1500 SC injection of 450 mg once weekly starting from Week 12 (Day 85). Only the first 2 enrolled participants received 4 weekly REGN1500 450 mg SC doses at weeks 12, 13, 14, and 15 per the protocol. This dose regimen was removed under protocol amendment 4. Participants were followed for a period of 24 weeks (through Week 26 \[Day 183\]) after the last dose of study drug in the main study period.
Trial: NCT02038452
Drug: Depo-Medrone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid Injection
Trial: NCT00859183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral
Trial: NCT01706198
Drug: inhaled corticosteroid with or without a long acting beta2-agonist
RxNorm normalized name: Sinex Long-Acting Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS alone or in combination with a long acting bronchodilator
Trial: NCT02116530
Drug: Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral or IV
Trial: NCT02300376
Drug: Dosage of Calcium edetate de sodium
RxNorm normalized name: edetate calcium
DrugBank: Edetate sodium (DB13404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There is no medical data for the use of Calcium edetate de sodium as a tracer to assess GFR. Calcium edetate de sodium is a treatment for lead intoxication. The extension of use as a tracer comes from its exclusive elimination by glomerular filtration. Plasma and renal clearance of Calcium edetate de sodium and Inulin will be measured for every included patient during a hospital day care (V1). For transplanted patients, plasma clearance of Calcium edetate de sodium will be repeated within one week (more or less 48hours) during annual medical check-up of renal transplantation.
Trial: NCT05139966
Drug: Mouthwash Product
RxNorm normalized name: Mouthwash Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants were requested to rinse 10 ml of the mouthwash 2 times / day (morning and evening) for 1 min after toothbrushing (a non-F dentifrice was used throughout the study).
Trial: NCT01225107
Drug: Inert Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert substance, 3 times per day in capsule form
Trial: NCT03056326
Drug: Placebo (Part 1 - SAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of placebo matching CHF6333 at each period
Trial: NCT03056326
Drug: Placebo (Part 2 - MAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily multiple doses of placebo matching CHF6333 for 14 days
Trial: NCT01776047
Drug: Exforge®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01776047
Drug: G-0081
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04646278
Drug: Hyperemic stimuli
RxNorm normalized name: STIMULEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperemic simuli of coronary flow by adenosine or nicorandil injection
Trial: NCT00647608
Drug: Inderal® LA Capsules 160 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160mg, single dose fed
Trial: NCT01114113
Drug: pancelipase/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZenPep 20000 units of lipase will be provided for the participant to take with a trigger meal or an identical placebo. This will only be given to those participants willing to consume 2 more identical trigger meals and will not be given for the initial baseline non-trigger and baseline trigger meal. In both of these arms, patients will also be swallowing the SmartPill Capsule.
Trial: NCT01231347
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously on days 1 and 15 of a 28 day cycle
Trial: NCT03849443
Drug: Vitamin C 250 MG Oral Tablet
RxNorm normalized name: vitamin C 250 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral method of placebo
Trial: NCT00606684
Drug: GW642444 3mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT00606684
Drug: GW642444 12.5mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW642444 12.5mcg
Trial: NCT00606684
Drug: GW642444 25mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW642444 25mcg
Trial: NCT00606684
Drug: GW642444 50mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW642444 50mcg
Trial: NCT02763579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous infusion was administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).
Trial: NCT00006721
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00006721
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03760133
Drug: Duolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants included in this group will be taken probiotics for 1 month after bowel preparation for colonoscopy.
Trial: NCT00406094
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00135733
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00273910
Drug: gp100:209-217 (210M)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02671773
Drug: Inhaled corticosteroid dose/type
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01241773
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 75 mg capsules once daily for 7 days
Trial: NCT01241773
Drug: TMC435
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 75 mg capsules once daily for 14 days
Trial: NCT00973271
Drug: 290 mg DCCR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 290 mg diazoxide choline
Trial: NCT00973271
Drug: 435 mg DCCR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 435 mg diazoxide choline
Trial: NCT00973271
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid
Trial: NCT01882400
Drug: Bisphosphonate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with Calcium, vitamin D and a weekly bisphosphonate. Comparison of bone mass, fracture rate, pain intensity and scoliosis progression before and after treatment
Trial: NCT01998685
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00377728
Drug: GSK256066
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01410383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets taken daily
Trial: NCT02579083
Drug: MB66
RxNorm normalized name: Metformin and Biguanide 66
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
Trial: NCT02579083
Drug: Placebo Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo film is composed of the identical excipients as MB66 without the monoclonal antibodies.
Trial: NCT01764854
Drug: Placebo (in-patient)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, size and color matched to experimental drug administered in a CPU
Trial: NCT01764854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, size and color matched to experimental drug
Trial: NCT01087879
Drug: Desogestrel-Ethinyl Estradiol contraceptive pill
RxNorm normalized name: desogestrel / ethinyl estradiol Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 microg Desogestrel and 20 microg Ethinyl Estradiol combination. One pill once a day for 9 weeks, continual administration.
Trial: NCT01087879
Drug: Etonogestrel-Ethinyl Estradiol vaginal ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etonogestrel-Ethinyl Estradiol vaginal ring, which consists of 11,7 mg etonogestrel and 2,7 mg ethinyl estradiol. It delivers 0,120 mg etonogestrel and 0,015 mg ethinyl estradiol per day. Treatment continues continual for 9 weeks and the vaginal ring is changed every three weeks.
Trial: NCT01087879
Drug: Norelgestromin-Ethinyl Estradiol contraceptive patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A combination transdermal contraceptive patch with 6 mg of norelgestromin and 600 microg of ethinyl estradiol. It delivers 203 microg of norelgestromin and 33,9 microg ethinyl estradiol per day. A continual use of patch for 9 weeks and the patch is changed every week.
Trial: NCT01486706
Drug: Placebo drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will titrate medications similar to the active drug group
Trial: NCT00040859
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01464359
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On Days 7 and 6 pre-transplant, 60 mg/kg intravenously (IV) over 2 hours with a high volume fluid flush and mesna per institutional guidelines.~Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 5, 4, 3 and 2 pre-transplant; 50 mg/kg/day IV over 2 hours.
Trial: NCT00647049
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 8000mg/m2 i.v., max. 2 cycles
Trial: NCT03273387
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.
Trial: NCT01580358
Drug: Shen-Mai San
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).
Trial: NCT02101203
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no